Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer

被引:4
作者
Nonaka, Michiko [1 ]
Sato, Seiya [2 ]
Osaku, Daiken [1 ]
Sawada, Mayumi [1 ]
Kudoh, Akiko [1 ]
Chikumi, Jun [1 ]
Sato, Shinya [1 ]
Oishi, Tetsuro [1 ]
Harada, Tasuku [1 ]
机构
[1] Tottori Univ, Sch Med, Dept Obstet & Gynecol, 36-1 Nishicho, Yonago, Tottori 6838504, Japan
[2] Iwate Med Univ, Sch Med, Dept Obstet & Gynecol, 19-1 Uchirnaru, Morioka, Iwate 0208505, Japan
来源
GYNECOLOGIC ONCOLOGY REPORTS | 2018年 / 26卷
关键词
Bevacizumab; Gastrointestinal perforation; Recurrent ovarian cancer; Salvage chemotherapy;
D O I
10.1016/j.gore.2018.08.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian cancer (OC). Bev is generally well-tolerated; however, it has a characteristic toxicity profile. In particular, gastrointestinal perforation (GIP) is a rare but serious side effect that can be lethal. A 55-year-old woman with recurrent OC had an episode of GIP during third-line chemotherapy comprising Bev and topotecan (TPT). Bev was discontinued while TPT was continued as monotherapy. Three months after discontinuation of Bev, the patient presented with left lower abdominal pain and was diagnosed with a second GIP. She had emergent surgery. One year later, she is still alive and healthy, and is continuing TPT. This is the first report of recurrent GIP after discontinuation of Bev. Our case suggests that physicians should be aware of GIP even after the discontinuation of Bev.
引用
收藏
页码:21 / 23
页数:3
相关论文
共 15 条
[1]  
[Anonymous], 2004, AV
[2]   Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].
Badgwell, B. D. ;
Camp, E. R. ;
Feig, B. ;
Wolff, R. A. ;
Eng, C. ;
Ellis, L. M. ;
Cormier, J. N. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582
[3]   The pharmacological bases of the antiangiogenic activity of paclitaxel [J].
Bocci, Guido ;
Di Paolo, Antonello ;
Danesi, Romano .
ANGIOGENESIS, 2013, 16 (03) :481-492
[4]   Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].
Cannistra, Stephen A. ;
Matulonis, Ursula A. ;
Penson, Richard T. ;
Hambleton, Julie ;
Dupont, Jakob ;
Mackey, Howard ;
Douglas, Jeffrey ;
Burger, Robert A. ;
Armstrong, Deborah ;
Wenham, Robert ;
McGuire, William .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186
[5]   Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials [J].
Geiger-Gritsch, Sabine ;
Stollenwerk, Bjoern ;
Miksad, Rebecca ;
Guba, Beate ;
Wild, Claudia ;
Siebert, Uwe .
ONCOLOGIST, 2010, 15 (11) :1179-1191
[6]   What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? [J].
Han, Ernest S. ;
Monk, Bradley J. .
GYNECOLOGIC ONCOLOGY, 2007, 105 (01) :3-6
[7]   Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis [J].
Hapani, Sanjaykumar ;
Chu, David ;
Wu, Shenhong .
LANCET ONCOLOGY, 2009, 10 (06) :559-568
[8]   Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers [J].
Martin, Jovana Y. ;
Urban, Renata R. ;
Liao, John B. ;
Goff, Barbara A. .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (05)
[9]   Profile of bevacizumab in the treatment of platinumresistant ovarian cancer: current perspectives [J].
McClung, E. Clair ;
Wenham, Robert M. .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2016, 8 :59-75
[10]   Bevacizumab toxicities and their management in ovarian cancer [J].
Randall, Leslie M. ;
Monk, Bradley J. .
GYNECOLOGIC ONCOLOGY, 2010, 117 (03) :497-504